AAPGAscentage Pharma Group International
The schedule
- Tue1Dec
Escalating geopolitical headwinds and potential legislative restrictions under the Trump administration targeting Chinese biotech firms.
- Thu25Mar
Full-year 2026 earnings release, providing an updated cash position, R&D expense trajectory, and forward guidance for 2027.
- Thu25Mar
- Thu24Jun
- Thu23Sep
Past
- Thu24Sep
Actual outcome: Mixed · $17.36 at outcome
Price at outcome date was between bear floor ($16.49) and bull target ($18.23).
- Sun31May
Actual outcome: Bear · $17.56 at outcome
Ascentage Pharma presented multiple clinical datasets at ASCO 2026, including updates on its core drug olverembatinib for CML and alrizomadlin for pediatric solid tumors. Despite the breadth of data shared, the stock fell 10.2% following the event, indicating that the trial results failed to impress investors or meet the efficacy and safety expectations required to drive shares higher.
Key clinical updates on olverembatinib and other hematology assets at the American Society of Hematology Annual Meeting.
- Sun31May
Actual outcome: Bear · $17.56 at outcome
Ascentage Pharma presented multiple clinical datasets at ASCO 2026, including Phase Ib results for its core drug olverembatinib in CML and its MDM2-p53 inhibitor alrizomadlin in pediatric solid tumors. The pipeline updates failed to catalyze investor enthusiasm, resulting in a 10.2% decline in the stock over the following month as the market likely viewed the trial data as underwhelming.
Presentation of mid-to-late stage oncology pipeline data at the European Society for Medical Oncology congress.
- Sun31May
Actual outcome: Bear · $16.48 at outcome
Ascentage Pharma reported in-line EPS of -$6.92 and presented multiple clinical datasets at ASCO 2026, including updates on olverembatinib and alrizomadlin. Despite these clinical updates, the lack of upside surprises in the data and financials failed to generate positive momentum, leading the stock to decline 10.2% toward the bear floor.
Market evaluation of AAPG's H1 2026 interim financials, focusing on cash runway, ATM utilization, and clinical progress.
- Fri15May
Actual outcome: Bear · $17.60 at outcome
The stock fell 9.7% and breached the bear floor of $21.50. While Ascentage Pharma presented clinical data from multiple trials at ASCO and the European Hematology Association Congress, these updates failed to offset overarching market concerns regarding the company's severe net loss and $1.98B debt load. The looming threat of dilutive equity financing or ATM utilization to extend its cash runway ultimately drove the share price lower.
Given a severe net loss of $639M in Q4 2025, AAPG may need to utilize its ATM or execute a secondary offering to pad its $2.47B cash reserve against its $1.98B debt load.
